IBS vs. IBD: How Doctors Tell Them Apart

Three letters apart, and almost nothing else in common. IBS and IBD produce overlapping symptoms — cramping, urgency, unpredictable bowels — but they are different kinds of problem, they carry different risks, and they are treated in completely different ways.

The distinction is not something you can settle at home. It is, however, worth understanding before an appointment, because knowing which details matter changes what you think to mention.

The Core Difference: Damage You Can See

Inflammatory bowel disease — Crohn's disease and ulcerative colitis — is immune-driven inflammation that physically damages the bowel wall. Put a camera in and you find ulcers, bleeding, and inflamed tissue. Take a biopsy and the damage shows under a microscope. It is a structural disease with visible evidence.

Irritable bowel syndrome leaves no such trace. The same camera finds a bowel that looks entirely normal. IBS is a disorder of gut-brain interaction: the signaling between the gut and the nervous system is disturbed, so ordinary digestion produces pain and disordered motility. The symptoms are real and measurable in their effects; the tissue is not damaged.

Crohn’s and Ulcerative Colitis Are Not Interchangeable

IBD is an umbrella over two diseases that behave differently, and the distinction shapes treatment. Ulcerative colitis is confined to the colon and rectum, and the inflammation is continuous — it starts at the rectum and extends upward without skipping. It affects the innermost lining rather than the full thickness of the bowel wall.

Crohn's disease can appear anywhere from mouth to anus, most often at the junction of the small and large intestine, and it is patchy: inflamed segments sit between stretches of healthy tissue, which is where the term “skip lesions” comes from. It also penetrates the full thickness of the wall, and that depth is what produces the complications ulcerative colitis largely does not — strictures where repeated healing narrows the bowel, and fistulas where inflammation tunnels through to another organ or the skin.

A minority of cases resist classification for a time and are labelled indeterminate or IBD-unclassified, which is a real diagnostic category rather than a failure of testing. The label can change as the pattern declares itself over years.

One Is Common, the Other Is Not

Scale is the first thing that shifts the odds. A 33-country Rome Foundation survey of more than 73,000 adults found that over 40 percent meet criteria for at least one disorder of gut-brain interaction — the family IBS belongs to. IBD is a different order of magnitude: prevalence has passed 0.3 percent of the population in North America and much of Europe, and it is rarer elsewhere.

So if you have gut symptoms and no alarm features, IBS is statistically far more likely. That is a reason for reassurance, not for skipping the appointment — the whole point of the alarm features below is that they are what shifts the odds.

The Signs That Point Toward IBD

These are the features doctors treat as reasons to investigate rather than reassure. None of them is proof of IBD, and each has other explanations — but each one moves you out of the straightforward-IBS category:

• Visible blood in the stool, or stools that are black and tarry
• Unintentional weight loss you did not set out to achieve
• Symptoms that wake you from sleep, rather than easing overnight
• Fever alongside the gut symptoms
• Anemia, or a family history of inflammatory bowel disease
• Symptoms that begin for the first time after about age 50

Timing separates them too. IBS pain is typically tied to bowel movements and often eases after one. IBD symptoms tend to run on their own schedule, including at night, and come in flares that last weeks rather than hours.

Where the Symptoms Overlap

How Doctors Actually Tell Them Apart

The usual first step is a stool test for fecal calprotectin, a protein released by white cells in an inflamed bowel. A 2023 meta-analysis of 17 studies covering nearly 2,000 patients found it reliably separates IBD from IBS, performing best at a cut-off of 50 micrograms per gram. A low result makes IBD unlikely; a raised one is the trigger for a colonoscopy, which is what actually confirms it.

IBS is diagnosed differently, and one point in the current gastroenterology guideline is often missed: it should be a positive diagnosis based on the symptom pattern, not a label applied once every test comes back clear. The same guideline does advise testing for celiac disease and IBD in anyone whose IBS symptoms include diarrhea — so a reasonable workup is not the same as an exhaustive one.

What a Calprotectin Result Actually Tells You

Calprotectin is worth understanding in a little detail, because it is usually the first objective test ordered and it is widely misread as an IBD test. It is not. It is a measure of how many white cells are migrating into the bowel — a marker of intestinal inflammation from any cause.

Results come back in micrograms per gram of stool. Laboratories set their own cut-offs, but a low result generally points away from inflammation and a clearly elevated one points toward it. Between the two sits a grey zone that neither confirms nor excludes, and which usually means repeating the test or moving to endoscopy rather than treating the number as a verdict.

Several things raise calprotectin without IBD being present. Recent NSAID use is the most common — ibuprofen and naproxen irritate the gut lining directly, and a course taken for something unrelated can push a result up. Proton pump inhibitors can raise it. So can a recent gastrointestinal infection, diverticulitis, and colorectal cancer, which is part of why an unexplained elevation is investigated rather than dismissed. Telling your clinician what you have been taking is not a formality; it changes how the result is read.

The direction of the test's usefulness is also asymmetric. It is better at ruling inflammation out than at proving what is causing it, which suits its actual job: deciding who needs a colonoscopy and who can reasonably be spared one.

An IBS diagnosis usually arrives with a subtype attached, based on which stool pattern dominates: IBS-D when diarrhea leads, IBS-C when constipation does, and IBS-M when the two alternate. The label is not bureaucratic. It decides which treatments get tried first, and it can shift over time — so a subtype that no longer matches what you are experiencing is worth raising rather than working around.

What Each Diagnosis Means Going Forward

An IBS diagnosis means managing symptoms: dietary changes such as a trial of a low-FODMAP diet, gut-directed psychological therapy, and targeted medication for whichever pattern dominates. It does not damage the bowel and does not raise your risk of bowel cancer.

An IBD diagnosis means ongoing medical care, usually medication that suppresses the immune response, with monitoring to keep inflammation down. Left untreated it can cause strictures, fistulas, and — with long-standing colitis — an increased risk of bowel cancer. That is precisely why the alarm features are worth acting on rather than waiting out.

The low-FODMAP diet is worth describing properly, because it is frequently attempted badly. FODMAPs are short-chain carbohydrates that ferment readily in the gut, and they are spread across foods with nothing obvious in common — wheat, onion, garlic, apples, milk, legumes, and several sweeteners among them. The protocol has three phases, and only the first is the restriction people have heard of.

Phase one removes high-FODMAP foods for a few weeks to establish whether symptoms respond at all. Phase two reintroduces them one group at a time to find which ones actually matter for you, because most people react to some and not others. Phase three builds the least restrictive long-term diet consistent with what phase two found. Stopping after phase one — which is the common failure — leaves someone permanently avoiding foods they may well tolerate, and a narrower diet is worse for the microbiome, not better. Current guidance is that it is best done with a dietitian for exactly this reason.

The IBD path looks different in kind. Treatment aims at suppressing the immune response driving the damage, and the target is not simply feeling better but healing the lining itself — someone can feel well while inflammation continues quietly, which is why monitoring continues during remission. Calprotectin often reappears here as a way to track disease activity without repeating a colonoscopy each time.

The cost of confusing the two runs mostly in one direction. Treating IBD as though it were IBS means inflammation continues unchecked while the response is dietary, and damage accumulated in that window does not reverse. Treating IBS as suspected IBD costs a stool test and some worry. That asymmetry is the reason doctors investigate alarm features rather than waiting to see how things develop.

Whichever direction this is heading, the appointment goes better with specifics than with impressions. Worth writing down beforehand: when the symptoms began and whether anything coincided with the start, whether they wake you at night, what your stools have actually looked like including any blood, whether your weight has changed without you trying, every medication and supplement you take including NSAIDs, and any family history of Crohn's, colitis, or coeliac disease. That last one carries real weight, and it is the detail people most often forget to mention.